Unlock this StockReport nowClick to Unlock

2cureX AB

2CUREX SEK14.1 -1.9  -11.7%

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2012 2013 2014 2015 2016 2017 TTM 2018E 2019E CAGR / Avg
Revenue SEKm
Operating Profit SEKm
Net Profit SEKm
EPS Reported SEK
EPS Normalised SEK
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps SEK
Capex ps SEK
Free Cashflow ps SEK
Dividend ps SEK
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc SEKm
Working Capital SEKm
Net Fixed Assets SEKm
Net Debt SEKm
Book Value SEKm
Average Shares m
Book Value ps SEK +136.4%

FINANCIAL BRIEF: For the nine months ended 30 September 2018, 2cureX AB revenues was not reported. Net loss increased from SEK3.1M to SEK6.8M. Higher net loss reflects Personnel costs increase of 88% to SEK5.9M (expense), Depreciation of tangible and intangible increase of 31% to SEK264K (expense), Financial income/expense decrease from SEK1K (income) to SEK1K (expense). more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score  
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 30th Sep '18) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2018
31st Dec 2019

Price Target: N/A
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a () () () () () ()
Consensus Estimate
1m Change
3m Change
Broker Consensus Trend
Broker Recommendations for 2cureX AB
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts:

Named Brokers and Analysts
There are no named brokers.

Profile Summary

2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.

Directors: Povl-Andre Bendz (CHM) 55, Ole Thastrup (CEO) 64, Juergen Kupper (CEX) 52, Grith Hagel (OTH) 58, Maarten van der Linden (OTH) , Juan Farre (DRC) 52, Ulrich Spengler (DRC) 50, Joergen Drejer (IND) 62, Simon Hesse Hoffmann (IND) 39, Timm-H. Jessen (IND) 55,

No. of Employees: n/a No. of Shareholders: n/a

Last Annual December 31st, 2017
Last Interim September 30th, 2018
Shares in Issue 10,350,000
Free Float 10.2m (99.0%)
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange OMX Nordic Exchange Stockholm
Eligible for an ISA? a SIPP?

Address Box 159, LANDSKRONA, 261 22, Sweden
Phone +
Auditors Ohrlings PricewaterhouseCoopers AB

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2018.

Should you buy 2CUREX

Access 2CUREX Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis